Compare Hormel Foods Corp (HRL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Viatris Inc — how do they compare? Hormel Foods Corp trades at $25.04 (market cap $13.91B), while Viatris Inc trades at $17.32 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Hormel Foods Corp pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| HRL | VTRS | |
|---|---|---|
Market Cap | $13.91B | $19.79B |
Sector | Consumer Staples | Health |
52-Week High | $29.52 | $17.39 |
52-Week Low | $19.74 | $8.74 |
Enterprise Value | $15.91B | $32.00B |
Dividend Yield | 4.63% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $25.31, down 0.33% on the day, with a bullish technical outlook and consistent earnings beats. The stock shows a P/E of 29.87 and net income margin of 3.82%, supported by a recent dividend of $0.29. Revenue for 2025 was $12.11B, though net income declined to $478.20M. Analysts maintain a mixed consensus with a $26.33 price target, while the company focuses on portfolio streamlining, such as the sale of its Ceratti business in Brazil (PRNewsWire, 2026-06-29).
HRL offers a stable dividend yield and is near multi-year lows, presenting a value opportunity amid sector weakness. Risks include margin pressure from input costs and competitive threats in the consumer staples space. Institutional sentiment is cautious with 57% hold ratings, but technical indicators suggest potential upside if earnings momentum continues.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
